Terns Pharmaceuticals Operating Income Over Time
| TERN Stock | USD 41.90 0.63 1.48% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Terns Pharmaceuticals Performance and Terns Pharmaceuticals Correlation. Will Pharmaceuticals sector continue expanding? Could Terns diversify its offerings? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Terns Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Terns Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Terns's accounting equity. The concept of intrinsic value - what Terns Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Terns Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Terns Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Terns Pharmaceuticals and related stocks such as Tourmaline Bio, Oric Pharmaceuticals, and Precigen Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORIC | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.4 M) | (28.6 M) | (74.2 M) | (78.9 M) | (91.8 M) | (110.8 M) | (142.9 M) | (143 M) | (135.9 M) |
| PGEN | (82.4 M) | (82.4 M) | (75.2 M) | (58 M) | (70 M) | (146.9 M) | (125.2 M) | (137.9 M) | (505.6 M) | (86.3 M) | (86.3 M) | (91.9 M) | (75.7 M) | (99.8 M) | (135 M) | (121.5 M) | (127.6 M) |
| IMTX | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (33 M) | (69.7 M) | (86.3 M) | 30 M | (101.7 M) | (38.6 M) | (34.8 M) | (36.5 M) |
| ELVN | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (10.7 M) | (24.1 M) | (9.3 M) | (24.8 M) | (38.8 M) | (83.5 M) | (104.6 M) | (94.1 M) | (89.4 M) |
| NKTR | (5.7 M) | (123.9 M) | (141.2 M) | (120.1 M) | (16.5 M) | (29.4 M) | (112.9 M) | (59.6 M) | 687.9 M | (440 M) | (379.9 M) | (446.1 M) | (240.2 M) | (137.4 M) | (105.2 M) | (94.7 M) | (99.4 M) |
| RLAY | (49.9 M) | (49.9 M) | (49.9 M) | (49.9 M) | (49.9 M) | (49.9 M) | (49.9 M) | (49.9 M) | (49.9 M) | (84 M) | (55.8 M) | (364.7 M) | (299.3 M) | (373 M) | (372.5 M) | (302.7 M) | (317.9 M) |
| SNDX | (9.6 M) | (9.6 M) | (8.7 M) | (8.6 M) | (21.3 M) | (20.5 M) | (43.8 M) | (62 M) | (75.9 M) | (57.5 M) | (71.4 M) | 26.2 M | (151.8 M) | (230 M) | (339.7 M) | (273.1 M) | (259.4 M) |
| INBX | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (19.7 M) | (29.5 M) | (43.7 M) | (67.4 M) | (76.6 M) | (129.1 M) | (219.2 M) | (331.4 M) | (298.3 M) | (283.4 M) |
Terns Pharmaceuticals and related stocks such as Tourmaline Bio, Oric Pharmaceuticals, and Precigen Operating Income description
Operating Income is the amount of profit realized from Terns Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Terns Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Terns Pharmaceuticals | TERN |
| Classification | Israel Wall Street |
| Business Address | 1065 East Hillsdale |
| Exchange | NASDAQ Exchange |
USD 41.9
Check out Terns Pharmaceuticals Performance and Terns Pharmaceuticals Correlation. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Terns Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.